Addtion of Daratumumab to Standard Tx Assessed in Multiple Myeloma

This article originally appeared here.
Lower risk of disease progression, death for multiple myeloma patients ineligible for transplantation
Lower risk of disease progression, death for multiple myeloma patients ineligible for transplantation

HealthDay News — Bortezomib, melphalan, and prednisone, combined with daratumumab is associated with a lower risk of disease progression or death for patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation, according to a study published online December 12 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from December 9 to 12 in Atlanta.

Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca in Spain, and colleagues randomized 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone or with daratumumab until disease progression. 

Related Articles

The researchers found that the 18-month progression-free survival rate was 71.6% and 50.2% in the daratumumab and control groups, respectively, at a median follow-up of 16.5 months (hazard ratio for disease progression or death, 0.50). The overall response rate was 90.9 and 73.9%, respectively, and rate of complete response or better was 42.6 and 24.4%, respectively. In the daratumumab and control groups, 22.3 and 6.2%, respectively, had results below the threshold for minimal residual disease.

"Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than a regimen without daratumumab," the authors write.

The study was funded by Janssen Research and Development, the manufacturer of daratumumab.

Abstract
Full Text
More Information